$0.45
-0.04 (-8.51%)
Open$0.49
Previous Close$0.49
Day High$0.49
Day Low$0.43
52W High$3.69
52W Low$0.25
Volume—
Avg Volume2.58M
Market Cap25.95M
P/E Ratio—
EPS$-2.04
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,567.0% upside
Current
$0.45
$0.45
Target
$7.44
$7.44
$4.65
$7.44 avg
$8.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.30M | 4.98M | 4.38M |
| Net Income | -11,481 | -9,902 | -8,948 |
| Profit Margin | -0.2% | -0.2% | -0.2% |
| EBITDA | -10,930 | -11,209 | -8,630 |
| Free Cash Flow | -9,428 | -11,072 | -6,340 |
| Rev Growth | +3.9% | +11.7% | +7.6% |
| Debt/Equity | 0.42 | 0.41 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |